

## CURRICULUM VITAE

PADIPORN VASINANUKORN LIMUMPORNPETCH, MD.,Ph.D.

- Date of birth 4 March 1975
- Current position Head of Endocrinology and Metabolism Unit, Faculty of medicine, Prince of Songkla University
- Business Address: Division of Endocrinology and Metabolism,  
Department of Medicine, Faculty of Medicine, Prince of Songkla University,  
Hat-Yai, Songkla, Thailand 90110.  
Tel: 6674-45-1451, 6674-45-1463. Fax: 6674-42-9385.  
Mobile: +66804519414  
e-mail: [Padiporn@gmail.com](mailto:Padiporn@gmail.com); [Padiporn.I@psu.ac.th](mailto:Padiporn.I@psu.ac.th)
- Education:
- Year 1998: MD., Prince of Songkla University, Thailand (Honor)
  - Year 2002: Certified Board of Internal Medicine, Prince of Songkla University, Thailand
  - Year 2006: Certified Subboard of Endocrinology and Metabolism, Chulalongkorn University, Thailand
  - Year 2006: MS, Epidemiology, Chulalongkorn University, Thailand
  - Year 2022: Ph.D. in molecular endocrinology and epidemiology; University of Leeds, UK
- Relevant Clinical Trial and Research Experience including GCP Training:
1. An open-label, multi-centre, expanded access study of pasireotide s.c. in patients with Cushing's disease (Seascape) Protocol No. CSOM230B2406(2011- 2016)
  2. Rockall score risk assessment in GI bleeding with Dr Buncha Ovathranporn
  3. High HDL-C (>100) in Thai population with Prof. Dr Weeapun Khovidhunkit
  4. A multi-centre clinical trial of rosiglitazone on the progression of coronary atherosclerosis in T2DM (APPROACH2010) with Assistance professor Sompong Suwanwalaikorn

5. Audit in Thai medical record and causes of death with Prof. Dr. Tada Yipinsoi, Assistance Professor Rattana Leelawattana, Assistance Prof Pantip Chayakul
6. Genomic Thailand Project for Familial hypercholesterolemia
7. LCI699C2301: A Phase III, multicenter, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for treatment of patients with Cushing's disease

Other Activities Pertinent to Professional Qualifications:

- Member of The Royal College of Physician of Thailand.
- Member of Thai Medical Council.
- Member of The Endocrine Society of Thailand
- Member of Endocrine Society
- Member of European Society of Endocrinology

Prizes relevant to career

- Award in Psychiatry (medical student Yr 4)
- Award in the best Internal Medical Student with the top score (medical student Yr 5)
- Award in the overall highest score (medical student Yr 5)
- Award with honour in Bachelor degree of Medicine
- Young investigator award in Pituitary disease (2014)
- Presidential Poster Competition Endocrine Society, US (2018)
- 50<sup>th</sup> year of medical PSU: Alumni award (2022)

**Oral Presentation**

- **Limumpornpetch P**, Morgan AW, Tiganescu A, Pujades-Rodriguez Mar, Nyaga VN, Baxter PD, and Stewart PM. Mortality and Specific Causes of Death in Endogenous Cushing's Syndrome: A Systematic Review, Meta-Analysis and Meta-Regression, Journal of the Endocrine Society, Volume 5, Issue Supplement\_1, April-May 2021, Page A166, <https://doi.org/10.1210/jendso/bvab048.335>. Oral presentation online ENDO 2021 on 20 March 2021 14:15-15:15.

**The article had been mentioned as a largest-ever analysis of CS mortality in many media as**

- Press release highlight article in Endo 2021
- Endocrine News (by Endocrine Society) <https://endocrinenews.endocrine.org/new-analysis-finds-cushings-syndrome-triples-risk-of-death/>
- Medscape <https://www.medscape.com/viewarticle/949257?form=fpf>
- <https://www.eurekalert.org/news-releases/463787>
- The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 10, October 2022, Pages e4232–e4233, <https://doi.org/10.1210/clinem/dgac341>
- <https://www.healio.com/news/endocrinology/20210322/mortality-rate-in-cushings-syndrome-unacceptably-high>
- <https://cushingsdiseaseneews.com/news/despite-falling-mortality-rates-cushings-syndrome-still-triples-risk-of-death-study-finds/>
- <https://www.medpagetoday.com/meetingcoverage/endo/91808>

**Poster presentation (international)**

- Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease, May 2015, Endocrine Abstracts, DOI: [10.1530/endoabs.37.EP811](https://doi.org/10.1530/endoabs.37.EP811)
- An open-label, multicentre, single-arm, expanded-access study of subcutaneous (s.c.) pasireotide in patients with Cushing's disease (CD), May 2018, Endocrine Abstracts, DOI: [10.1530/endoabs.56.P861](https://doi.org/10.1530/endoabs.56.P861)
- **Limumpornpetch P**, Morgan AW, Pujades-Rodriguez Mar, Stewart PM and Tiganescu A. Hypoxia Drives 11 $\beta$ -hydroxysteroid Dehydrogenase Type 1 Expression To Exacerbate Anti-inflammatory And Anti-angiogenic Signalling In Human Skin Fibroblasts [Poster-SUN-407]. ENDO 2018: 100th Endocrine Society Annual Meeting. March 17-20, 2018. McCormick Place WestChicago, IL. **The poster had qualified for the Presidential Poster Competition and selected for 3-minute presentation.**
- **Limumpornpetch, P.**, Morgan, A. W., Tiganescu, A., Stewart, P. M., & Pujades-Rodriguez, M. (2020). MON-157 The Effect of Exogenous Cushing's Syndrome on All-Cause and Cause-Specific Mortality: A Systematic Review. Journal of the Endocrine Society, 4(Suppl 1), MON-157. Endo2020. Cancel due to COVID-19. <https://doi.org/10.1210/jendso/bvaa046.1620> [Poster-MON-157].
- **Limumpornpetch P**, Morgan AW, Tiganescu A, Pujades-Rodriguez Mar, Nyaga VN, PhD, Baxter PD, and Stewart PM. Real World Mortality and Specific Causes of Death in Chronic Oral Glucocorticoid Use: A Systematic Review, Meta-Analysis and Meta-Regression, Journal of the Endocrine Society, Volume 5, Issue Supplement\_1,

April-May 2021, Page 93. <https://doi.org/10.1210/jendso/bvab048.186>. electronic-Poster ENDO 2021.

- The poster was **selected for ENDO 2021 as Highlights Features and recorded as podcast. <https://endohighlights2021.com/medfyles/p-real-world-mortality-and-specific-causes-of-death-in-chronic-oral-glucocorticoid-use-a-systematic-review-meta-analysis-and-meta-regression>**

### Peer-reviewed publications

1. **Padiporn Limumpornpetch**, Ann W Morgan, Ana Tiganescu, Paul D Baxter, Victoria Nyawira Nyaga, Mar Pujades-Rodriguez, Paul M Stewart. The effect of endogenous Cushing's syndrome on all-cause and cause-specific mortality: A systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2022 Apr 29;dgac265. doi: 10.1210/clinem/dgac265. Online ahead of print.
2. Sherlock M, Scarsbrook A, Abbas A, Fraser S, **Limumpornpetch P**, Dineen R, Stewart PM. Adrenal Incidentaloma. *Endocr Rev.* 2020 Dec 1;41(6):775–820. doi: 10.1210/endrev/bnaa008. PMID: 32266384; PMCID: PMC7431180. <https://doi.org/10.1210/endrev/bnaa008>
3. Fleseriu M, Iweha C, Salgado L, Mazzuco TL, Campigotto F, Maamari R, **Limumpornpetch P**. Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study. *Front Endocrinol (Lausanne).* 2019 Jul 16;10:436. doi: 10.3389/fendo.2019.00436. PMID: 31379734; PMCID: PMC6646464.
4. Chayovan, T., **P. Limumpornpetch**, and K. Hongsakul, Success rate of adrenal venous sampling and predictors for success: a retrospective study. *Pol J Radiol*, 2019. 84: p. e136-e141.
5. Khovidhunkit W, Chartyingcharoen P, Siriwong S, **Limumpornpetch P**, Plengpanich W. Resequencing CETP, LIPC and LIPG genes in Thai subjects with hyperalphalipoproteinemia. *Am J Cardiol.* 2012 Jul 1;110(1):62-6. doi: 10.1016/j.amjcard.2012.02.052. Epub 2012 Mar 29. PMID: 22464213..
6. Gerstein, H.C., et al., Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation*, 2010. 121(10): p. 1176-87.
7. Snabboon T, Plengpanich W, Buranasupkajorn P, Khwanjaipanich R, **Vasinanukorn P**, Suwanwalaikorn S, Khovidhunkit W, Shotelersuk V. A novel germline mutation, IVS4+1G>A, of the POU1F1 gene underlying combined pituitary hormone deficiency.

Horm Res. 2008;69(1):60-4. doi: 10.1159/000111797. Epub 2007 Dec 4. PMID: 18059085.

8. **Vasinanukorn P**, Rerknimitr R, Sriussadaporn S, Wisedopas N, Kongkam P, Chaopapsomkul B, Snabboon T., Adrenal hemorrhage as the first presentation of hepatocellular carcinoma. Intern Med, 2007. 46(21): p. 1779-82.
9. Polamaung W, Wisedopas N, **Vasinanukorn P**, Pak-art P, Snabboon T. Asymptomatic bilateral giant adrenal myelolipomas: case report and review of literature. Endocr Pract, 2007. 13(6): p. 667-71.

### **Books, chapter**

**Padiporn Limumpornpetch** and Paul M. Stewart in Apparent Mineralocorticoid Excess in Encyclopedia of Endocrine Diseases (Second Edition), 2019, Publisher: Elsevier, ISBN: 978-0-12-812200-6